Novel Probiotic Treatment for Candida albicans Utilizing Antifungal Inhibitors of Lactobacillus acidophilus via a Bombyx mori Infection Model

Overview

Candidiasis refers to various infections attributable to the opportunistic yeast fungus Candida. These infections possess the ability to manifest in various forms specific to the location of colonization, and are capable of inducing bacterial endocarditis, candidemic septic shock, infections of the bloodstream, and in severe cases- death. One of the most prevalent strains of Candida is Candida albicans of the Saccharomycetaceae family. C.albicans has developed multidrug resistance due to the overuse of common candidiasis treatments such as itraconazole, fluconazole, and amphotericin B. This experiment identified and tested a novel probiotic treatment sourced from live Lactobacillus acidophilus to combat the increasing multidrug resistance of the C.albicans strain without compromising the effectiveness of candidiasis inhibition. A Bombyx mori infection model was used to host this interaction through induced candidiasis infection and direct injection of the novel treatment. The results of this experiment display a significant reduction in the pathogenicity of C.albicans infection with an 80% increase in the chance of survival after treatment (Chi-Square p= <0.0001). This demonstrates promise for potential utilization in medicinal development to address the rising concern of mortality rates associated with the increase in fungal infections. ILLINOIS

Competition history

• JSHS 2023 Category not listed

Resources

• National JSHS abstract book ↗

Related projects

Closest projects by meaning, across every fair and year in the corpus.